Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity

Prostate

Volumn 70, Issue 12, 2010, Pages 1274-1285

  Mahajan, Kiran ^a   Challa, Sridevi ^a   Coppola, Domenico ^a   Lawrence, Harshani ^a   Luo, Yunting ^a   Gevariya, Harsukh ^a   Zhu, Weiwei ^a   Chen, Y Ann ^a   Lawrence, Nicholas J ^a   Mahajan, Nupam P ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Ack1; AIM 100; AR; CRPC; Prostate cancer; Tissue microarray; TNK2; Tyrosine kinase inhibitor

Indexed keywords

4 AMINO 5,6 BIARYL FURO[2,3D]PYRIMIDINE; ACTIVATED CDC42 ASSOCIATED KINASE; AIM 100; ANDROGEN; ANDROGEN RECEPTOR; ANTIBODY; BICALUTAMIDE; EPIDERMAL GROWTH FACTOR; FLUTAMIDE; LIGAND; NEU DIFFERENTIATION FACTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TRANSCRIPTION INITIATION;

AMINO ACID SEQUENCE; ANDROGENS; ANIMALS; ANTIBODY FORMATION; CELL LINE, TUMOR; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOPEPTIDES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; RABBITS; RECEPTORS, ANDROGEN; SURVIVAL RATE;

EID: 77954584067     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21163     Document Type: Article

References (30)

1. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93(22):1687-1697.
2. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23(32): 8253-8261.
3. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9(4):401-406.
4. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332(21):1393-1398.
5. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, Njar VC, Brodie AM, Yu LR, Veenstra TD, Chen H, Qiu Y. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006;10(4):309-319.
6. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, Earp HS, Whang YE. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA 2007;104(20): 8438-8443.
7. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59(11):2511-2515.
8. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-39.
9. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ. High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy. J Urol 1998;159(1):149-153.
10. Mahajan NP, Whang YE, Mohler JL, Earp HS. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: Role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res 2005;65(22):10514-10523.
11. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002;277(32):29304-29314.
12. Galisteo ML, Yang Y, Urena J, Schlessinger J. Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proc Natl Acad Sci USA 2006;103(26): 9796-9801.
13. Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Riviera C, Cheng JQ, Schönbrunn E, Sebti SM, Earp SH, Mahajan NP. Ack1 mediated AKT/PKB Tyrosine 176 phosphorylation regulates its activation. PLoS ONE 2010;5(3):e1-17.
14. Modzelewska K, Newman LP, Desai R, Keely PJ. Ack1 mediates Cdc42-dependent cell migration and signaling to p130Cas. J Biol Chem 2006;281(49):37527-37535.
15. Eisenmann KM, McCarthy JB, Simpson MA, Keely PJ, Guan JL, Tachibana K, Lim L, Manser E, Furcht LT, Iida J. Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1999;1(8): 507-513.
16. van der Horst EH, Degenhardt YY, Strelow A, Slavin A, Chinn L, Orf J, Rong M, Li S, See LH, Nguyen KQ, Hoey T, Wesche H, Powers S. Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci USA 2005; 102(44):15901-15906.
17. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005;7(6):591-600.
18. DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Buchanan JL, Buckner WH, Cheng A, Faust T, Hsieh F, Huang X, Lee JH, Marshall TL, Martin MW, McGowan DC, Schneider S, Turci SM, White RD, Zhu X. Discovery of 4-amino-5,6-biarylfuro[ 2,3-d]pyrimidines as inhibitors of Lck: Development of an expedient and divergent synthetic route and preliminary SAR. Bioorg Med Chem Lett 2007;17(8):2305-2309.
19. Foloppe N, Fisher LM, Howes R, Kierstan P, Potter A, Robertson AG, Surgenor AE. Structure-based design of novel Chk1 inhibitors: Insights into hydrogen bonding and protein - ligand affinity. J Med Chem 2005;48(13):4332- 4345.
20. Mahajan NP, Earp HS. An SH2 domain-dependent, phosphotyrosine- independent interaction between Vav1 and the Mer receptor tyrosine kinase: A mechanism for localizing guanine nucleotide-exchange factor action. J Biol Chem 2003;278(43): 42596-42603.
21. Yokoyama N, Miller WT. Biochemical properties of the Cdc42- associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck. J Biol Chem 2003;278(48):47713-47723.
22. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-790.
23. Kraus S, Gioeli D, Vomastek T, Gordon V, Weber MJ. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res 2006;66(22):11047-11054.
24. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353(2):172-187.
25. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 2005;23(3):455-460. (Pubitemid 46224221)
26. Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 2007;100(4):765-769.
27. Gravis G, Bladou F, Salem N, Goncalves A, Esterni B, Walz J, Bagattini S, Marcy M, Brunelle S, Viens P. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol 2008;19(9):1624-1628.
28. Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007;7:142.
29. Lara PN Jr., Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: A California Cancer Consortium Study. Anticancer Drugs 2009;20(3):179-184.
30. Festuccia C, Gravina GL, Biordi L, D'Ascenzo S, Dolo V, Ficorella C, Ricevuto E, Tombolini V. Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Prostate 2009;69(14):1529-1537.